Search

Displaying results 2151 - 2160 of 4234 in total
  1. Drug

    P-113D

    go.drugbank.com/drugs/DB04987
    Experimental

    It is being pursued as a potential treatment for cystic fibrosis by Demegen, Inc.

  2. Drug

    Elivaldogene autotemcel

    go.drugbank.com/drugs/DB16746
    Approved

    Gene therapy with autologous hematopoietic stem cells was introduced and investigated as a possible treatment for patients with adrenoleukodystrophy.

  3. Drug

    Oxybutynin

    go.drugbank.com/drugs/DB01062
    ApprovedInvestigational

    It is often used as first-line therapy for OAB.[A185990] … [A185996,A185999] Oxybutynin, also marketed as Ditropan XL, is an anticholinergic medication used for the relief of overactive bladder symptoms that has been optimized for high levels of safety and

  4. Drug

    Tolazamide

    go.drugbank.com/drugs/DB00839
    Approved

    A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.

  5. Drug

    Pipotiazine

    go.drugbank.com/drugs/DB01621
    ApprovedInvestigationalWithdrawn

    Pipotiazine has actions similar to those of other phenothiazines. Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depr...

  6. Drug

    Sulfaphenazole

    go.drugbank.com/drugs/DB06729
    Approved

    Sulfaphenazole is a sulfonamide antibacterial.

  7. Drug

    Ledipasvir

    go.drugbank.com/drugs/DB09027
    Approved

    Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as ledipasvir. … Since 2014, ledipasvir has been available as a fixed dose combination product with [sofosbuvir] (tradename Harvoni) used for the treatment of chronic Hepatitis C.

  8. Drug

    Streptococcus pneumoniae type 3 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10321
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

  9. Drug

    Streptococcus pneumoniae type 4 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10322
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

  10. Drug

    Streptococcus pneumoniae type 5 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10323
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.